Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.61 |
| ▸ | METAP1 | P53582 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422957 | 0.91 | ACHE (0.65) | ACHECYP19A1METAP1MAOBMAP2K3 | |
| SCHEMBL9146594 | 0.88 | CYP19A1 (0.63) | CYP19A1METAP1ABCB1ARABCG2 | |
| SCHEMBL9148955 | 0.82 | CYP19A1 (0.59) | ACHECYP19A1MAOBLMNAMAP2K3 | |
| SCHEMBL9147933 | 0.81 | LMNA (0.64) | ACHECYP19A1LMNA | |
| SCHEMBL10957339 | 0.81 | KDM4E (0.62) | ACHEABCB1SLC6A2SLC6A3MAOB | |
| SCHEMBL13891933 | 0.80 | CYP19A1 (0.58) | ACHECYP19A1METAP1SLC6A2SLC6A4 | |
| SCHEMBL25732148 | 0.79 | ABCB1 (0.56) | ACHECYP19A1METAP1ABCB1AR | |
| SCHEMBL7573550 | 0.79 | METAP1 (0.56) | ACHECYP19A1METAP1MAOBMAP2K3 | |
| SCHEMBL6286139 | 0.78 | CYP19A1 (0.55) | ACHECYP19A1METAP1MAOBLMNA | |
| SCHEMBL6591252 | 0.78 | KDM4E (0.67) | CYP19A1ABCB1ARABCG2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013068785-A1 | INDANONE AND INDANDIONE DERIVATIVES AND HETEROCYCLIC ANALOGS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-16 | — | — | WO | disclosed |
| WO-2009053443-A2 | INDANE COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2009-04-30 | — | — | WO | disclosed |
| US-7482340-B2 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2009-01-27 | — | — | US | disclosed |
| US-7482340-B2 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2009-01-27 | — | — | US | disclosed |
| US-7425568-B2 | Compounds, which are potent inhibitors of Na+ /Ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2008-09-16 | — | — | US | disclosed |
| US-7425568-B2 | Compounds, which are potent inhibitors of Na+ /Ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2008-09-16 | — | — | US | disclosed |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2006-10-26 | — | — | US | disclosed |
| EP-1412343-B1 | COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORP (FI) | 2006-08-30 | — | — | EP | disclosed |
| EP-1583759-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2005-10-12 | — | — | EP | disclosed |
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2004-11-25 | — | — | US | disclosed |
| WO-2001051472-A9 | NEW IMIDAZOLE DERIVATIVES | ORION CORP (FI) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003006452-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2003-01-23 | — | — | WO | disclosed |
| EP-1261588-A1 | NEW IMIDAZOLE DERIVATIVES | ORION CORPORATION (FI) | 2002-12-04 | — | — | EP | disclosed |
| US-6388090-B2 | IMIDAZOLE DERIVATIVES CONTAINING BICYCLIC AROMATIC OR AN HETEROCYCLIC RING FUSED WITH BENZENE EXHIBIT AFFINITY FOR ALPHA2 ADRENOCEPTORS SO TREATS THE DISEASE AFFECTED BY ALPHA2 ADRENOCEPTORS, E.G. NUROLOGICAL, PSYCHIATRIC OR COGNITION | ORION CORPORATION (FI) | 2002-05-14 | — | — | US | disclosed |
| US-20010056109-A1 | Imidazole derivatives | ORION CORPORATION (FI) | 2001-12-27 | — | — | US | disclosed |
| EP-0848699-B1 | BENZOCYCLOALKENE COMPOUNDS WITH MELATONINE RECEPTOR BINDING AFFINITY, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001051472-A1 | NEW IMIDAZOLE DERIVATIVES | ORION CORPORATION (FI) | 2001-07-19 | — | — | WO | disclosed |
| US-5922771-A | MELATONIN RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| EP-0848699-A1 | BENZOCYCLOALKENE COMPOUNDS WITH MELATONINE RECEPTOR BINDING AFFINITY, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-06-24 | — | — | EP | disclosed |
| WO-1997005098-A1 | BENZOCYCLOALKENE COMPOUNDS WITH MELATONINE RECEPTOR BINDING AFFINITY, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | CACNA1E, KCNN4, RYR2 | ACHE 3357/4885CYP19A1 2036/4885METAP1 4733/4885 |
| US-20010056109-A1 | Imidazole derivatives | ADRB2, ADRB1, ADRA1D | ACHE 1388/4885CYP19A1 1178/4885METAP1 2475/4885 |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | SLC8B1, CACNA1A, MCU | ACHE 1692/4885CYP19A1 2119/4885METAP1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.